Skip to content

ICH

ICH Q7 18.16

18. AGENTS, BROKERS, TRADERS, DISTRIBUTORS, REPACKERS, AND RELABELLERS

Section text

In general, process controls should take into account:

- Maintenance of the Working Cell Bank (where appropriate);

- Proper inoculation and expansion of the culture;

- Control of the critical operating parameters during fermentation/cell culture;

- Monitoring of the process for cell growth, viability (for most cell culture processes) and productivity where appropriate;

- Harvest and purification procedures that remove cells, cellular debris and media components while protecting the intermediate or API from contamination (particularly of a microbiological nature) and from loss of quality;

- Monitoring of bioburden and, where needed, endotoxin levels at appropriate stages of production; and

- Viral safety concerns as described in ICH Guideline Q5A Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin.

Source: International Council for Harmonisation (ICH) · © ICH. Per the legal notice in each guideline, the document may be used, reproduced and distributed provided ICH's copyright is acknowledged; any adaptation or translation must be labelled as such and must not imply ICH endorsement. · retrieved 2026-11-15

Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.